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Seroepidemiological studies of tetanus in Africans have focused mainly on adults espe-
cially pregnant women and data on children are scarcely reported. We investigated the
seroprevalence of protective immunity level, determined risk factors for non-protection
against tetanus, and evaluated the performance of Tetanos Quick Stick® (TQS) among
hospitalized children aged 1–9 years in Nigeria. Blood IgG antibody levels to tetanus was
determined using enzyme-linked immunosorbent assay (ELISA) in the laboratory and TQS
(an immunochromatographic test) at the bedside for 304 children admitted into emergency
unit of a tertiary hospital in Ibadan, Nigeria. Demographic information and vaccination his-
tory were also collected.TQS results were compared with anti-tetanus antibody measured
by ELISA using seroprotection cut-off of 0.1 IU/ml. Seroprevalence of protective level of
immunity against tetanus using ELISA and TQS methods was 44.7 and 45.4% respec-
tively. Protective level of immunity increased as age increases. Of the seven potential
factors assessed, male gender and being second or more position among mother’s chil-
dren were independent predictors of non-protective level of immunity. Absence of history
of recent tetanus toxoid injection was significantly associated with non-protective level of
immunity in univariate analysis but not logistic regression model.The agreement between
the ELISA and theTQS results was good with a k coefficient of 0.931.TQS sensitivity was
95.7%, specificity 97.6%, positive predictive value 98.0%, and negative predictive values
96.0%. This study showed that lack of protective immunity against tetanus is common;
few demographic characteristics correctly predict non-protection and IgG antibody levels
to tetanus was accurately detected by TQS.
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INTRODUCTION
Tetanus is an acute neurological but vaccine-preventable disease
caused by Clostridium tetani that causes significant morbidity and
mortality among children in developing countries (1). A recent
systematic analysis of data from 2000 to 2010 showed that neona-
tal tetanus decreased in Africa at an annual rate sufficient to attain
the Millenium Development Goal 4 and it accounted for 20,000–
276,000 neonatal deaths (1% of all child mortality) in 2010 (2).
On the other hand, post-neonatal tetanus accounted for less than
1% of global child mortality (2). In Nigeria, of the five million
babies born annually, 240,000 (4.8%) die within the first 4 weeks
of life and tetanus accounts for up to 20% of these deaths (3).
Total eradication of tetanus is not likely because tetanus spores
are found everywhere in the soil and stool of animals, but vac-
cination against the diseases can effectively protect susceptible
individuals (4). The World Health Organisation (WHO) recom-
mends administration of three doses of tetanus toxoid (TT) as one
of the vaccines for routine immunization program to all infants
and booster doses during adolescence and pregnancy in order to
achieve elimination of tetanus in early childhood (5). Many of
the countries in sub-Saharan African are implementing this rec-
ommendation and they have either attained the elimination of
tetanus or making substantial progress toward achieving this goal
but some are not (6). Nigeria is one of the 27 countries currently
accounting for 90% of the global burden of the disease (6–9).
Despite the recent scaling up of routine immunization program
in Nigeria, tetanus continues to affect children and many are dying.
For instance, post-neonatal tetanus is a significant cause of emer-
gency admission and a major killer of infants in Ibadan, Nigeria.
An anecdotal observation of admissions into the children emer-
gency ward of the University College Hospital (UCH) revealed that
16 out 767 children aged 1–9 years admitted in 2011 had tetanus
(2.1%) and 9 of these cases died giving a case fatality rate of 56.3%
(unpublished data). The persistence of tetanus and the high case
fatality rate in spite of the availability of potent vaccine underscore
the need to do seroepidemiological studies. Children presenting
in the hospitals for whatever reason, especially the emergency unit
provide a good opportunity to identify those who are not protected
against tetanus and they could be offered the vaccine (10). A his-
tory of vaccination is often obtained by physician for the purpose
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of making decision but this does not necessarily imply that the
patient had attained protective immunity (11). Instead of proper
identification, many physicians habitually administer vaccines and
tetanus immunoglobulin whether or not there is sufficient evi-
dence to do so. Though the risk of injection of human blood
products may be small but should nonetheless, not encourage
its prescription. With good diagnostic tests to determine tetanus
immunity status accurately, this practice and its potential risks
could be averted.
The Enzyme-Linked Immunosorbent assay (ELISA) test can
be used as the gold standard, with a cut-off value of 0.1 IU/ml for
anti-tetanus IgG level, to define protection against tetanus (5). This
cut-off is considered being protective in many studies and has been
described as adequate (5, 11–14). However, ELISA test is not read-
ily available in health centers in many developing countries where
tetanus is still a public health problem; immunization status in
this setting is normally assessed from the immunization history
reported by the caregivers of children, which has been shown to be
inaccurate (14, 15). The consequences of this are over- and under-
prescription of vaccine and tetanus immunoglobulin, a human
blood product. The determination of the level of serum anti-TT
antibodies by an ELISA method allows an objective evaluation of
tetanus immunity; however, this technique requires a blood sam-
ple and several hours of highly technical work, which cannot meet
the emergency units’ requirements. An alternative to ELISA test
is an immunochromatographic test [Tetanos Quick Stick® (TQS),
Gamma, Angleur, Belgium], which makes the semi-quantitative
evaluation of anti-tetanus immunity possible at the bedside is now
available. This test can be carried out on serum or whole blood,
and can be performed on a drop of blood from a finger prick.
TQS has been shown to be reliable when compared with ELISA in
previous studies (12, 13, 16) but not in Nigeria. The present study
was carried out to investigate the prevalence of protective level
of immunity and risk factors for non-protection against tetanus
infection among hospitalized children aged 1–9 in Nigeria. The
performance of TQS in determining tetanus immunity was also
evaluated against ELISA method.
MATERIALS AND METHODS
STUDY DESIGN AND PATIENTS RECRUITMENT
This prospective observational study was performed in the chil-
dren emergency ward of the UCH, Ibadan, Nigeria. The UCH is
located in an urban area of Ibadan city and had an average of
2500 yearly admissions. Children aged 1–9 years admitted during
a 6-month period (April to September, 2012) were consecutively
recruited into the study. To avoid interference with the current pro-
phylaxis policy of the hospital, patients presenting with wounds
were excluded from the study. Other exclusion criteria were per-
sons under 1 year, prior inclusion in the same study and those
who presented with tetanus. Of the 337 eligible patients, 304 par-
ticipated in the study after their mothers or caregivers signed the
informed consent form.
SAMPLE SIZE JUSTIFICATION
We postulated that the prevalence of protective immunity against
tetanus among children to be 45.3% [based on a survey by Brabin
et al. (17)]. We calculated that recruiting 304 out of 375 eligible
gives an absolute precision of 2.43% and at 95% confidence level
using the Win Episcope 2.0 software.
DATA COLLECTION
An interviewer-administered questionnaire was used to obtain
demographic information and vaccination history. A child was
considered to be fully immunized if he or she had received all of
the following vaccines: a dose of Bacille Calmette Guerin (BCG),
four doses of oral polio (OPV), three doses of diphtheria, per-
tussis, and tetanus (DPT), three doses of hepatitis B (HBV), and
one dose of measles by the age of 12 months. Presentation of a
vaccination card or any other official document concerning vacci-
nation history was noted in the questionnaire. Sociodemographic
characteristics (gender, age, number of siblings, position among
mother’s children, ethnicity, and parents’ educational level and
occupation) and history TT injection 1 year before the study were
also collected. Caregivers were questioned about past medical his-
tory (medical and surgical antecedents), date of last trauma with
or without a wound, date of childbirth, and consultation with
a general practitioner to corroborate claims of tetanus vaccina-
tions. A 3 ml blood sample was collected from each participant
into a plain specimen bottle and serum was obtained and kept
in kept at −20°C until laboratory analysis. Weight and height of
all participants were measured and compared with WHO refer-
ence population to obtain the z-scores for weight-for-height using
the WHO AnthroPlus, a software for the global application of the
WHO Reference 2007 for monitoring the growth of school-age
children and adolescents as described previously (18).
EVALUATION OF TETANUS IMMUNITY
Immunity against tetanus was evaluated using ELISA in the labora-
tory and TQS by the bedside. Anti-tetanus IgG concentrations were
measured by ELISA as described in two previous studies (15, 19).
Concisely, sera were incubated on TT-coated ELISA plates. Fixed
IgG was revealed by the addition of peroxidase-conjugated anti-
human IgG after incubation and washing. The anti-tetanus IgG
concentrations of the samples were assessed by reference to a stan-
dard curve constructed from serial dilutions of a preparation of
human tetanus immunoglobulin with a known concentration of
anti-tetanus IgG (Tetabulin 250, Baxter Bioscience, and Deerfield,
IL, USA).
The TQS is based on an immunochromatographic method
which has been described in a previous study (11). All TQS tests
were performed using whole blood, and were interpreted after
10 min according to the manufacturer’s recommendation. Results
(whether positive, negative, or equivocal) were recorded in the
patient’s questionnaire. A research assistant was trained on the use
and interpretation of the TQS results before starting the study. All
tests kits were carefully preserved and reviewed by the investigators
to ascertain correctness of the results. Six tests reported as equiv-
ocal by the assistant nurse were repeated by the main investigator
(AEO) who decided they were positive result without being aware
of the ELISA result.
ETHICAL CONSIDERATIONS
Ethical approval was obtained from the Oyo State Research Ethi-
cal Review Committee, Ministry of Health, Oyo state secretariat,
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Ibadan. Written informed consent was obtained from the partic-
ipants’ parents or caregivers after the purpose of the study was
explained to each of them in the language they understood. Serial
numbers and codes were used to identify participants. The ques-
tionnaires were kept in a secured place accessible to the researcher
alone.
DATA ANALYSIS
Socioeconomic classes of participants were assessed using the
method employed by Oyedeji (20) in a similar setting. Data were
first analyzed using descriptive statistics [medians, interquartile
range (IQR), frequencies]. Seroprevalence among the different
categories were calculated. Bivariate analysis was used to assess
associations between various potential risk factors and protection
based on ELISA results. Those factors with significant associa-
tions were included in a logistic regression analysis to exclude the
effects between the variables and to identify independent predic-
tors of a non-protective antibody level. p-Values less than 0.05
were considered significant. These statistical analyses were per-
formed with SPSS 17.0 for Windows (SPSS, Chicago, IL, USA).
The performance of immunity status determined using TQS was
assessed by determining the sensitivity, specificity, positive and
negative predictive values (NPV), with 95% confidence intervals
(CI). ELISA was considered to be the gold standard. We used
a threshold of 0.1 IU/ml of serum to define positive results in
ELISA.
RESULTS
CHARACTERISTICS OF STUDY POPULATION
The study patients comprised 170 (55.9%) males and 134 (44.1%)
females giving a male to female ratio of 1.3:1. Mean age of
participants was 3.7± 2.3 years and children 5 years and below
constituted 79.3%. There was no significant difference between
male and female patients’ distribution by age (Figure 1). Mean
age (3.6± 1.1 years) and gender distribution (40 male and 31
female) of children who did not participate in the study were
not statistically different from those of the study patients. Of
the 304 patients, 24 (7.9%), 98 (32.2%), and 182 (59.9%) were
from high, middle, and low socioeconomic classes and major-
ity (80.3%) were from the Yoruba ethnic group. Forty-six percent
(n= 140) of the study patients were first child of their mothers and
median numbers of children in the families was 3 (range= 1–7).
Almost a quarter (24.7%) of the study patients were underweight
(weight-for-height z-score<2.0).
TETANUS IMMUNIZATION HISTORY OF STUDY PARTICIPANTS
Table 1 displays the tetanus immunization history of the study
patients. History of vaccination was confirmed by examining the
vaccination card and history taking in 196 (64.5%) and obtained
from only history taking from the caregivers in 108 (35.5%) of
patients who participated in the study. Only 90 (29.6%) of study
patients were fully vaccinated according to the Nigeria National
Programme on Immunization (NPI) by the age of 10 months.
Uptake rate for DPT-3 was 19.1% as indicated by vaccination card
and 29.9% as indicated by history. Combining evidence from vac-
cination card and history suggested a total DPT-3 uptake rate of
49.0%. Only 25 (8.2%) participants had received at least a booster
FIGURE 1 | Distribution of study patients by age.
dose of TT injection after routine DPT vaccinations in infancy.
Stratifications of tetanus-related vaccination by gender and birth
position were as shown in Table 2. There is no association between
vaccination and gender as well as birth position.
PREVALENCE OF ANTI-TETANUS PROTECTION AMONG STUDY
PARTICIPANTS
Overall, the prevalence of seroprotection by ELISA was 44.7%
(95% CI= 39.1, 50.5%) and the prevalence of seroprotection by
TQS tests was 45.4% (95% CI= 39.7, 51.2%). Using ELISA test
results, proportions of children with seroprotection were signifi-
cantly more in females (74/134) than males (62/170), p= 0.001;
children who had history of recent TT injection (17/25) than
those who did not (119/279), p= 0.015; and among first born of
mothers (78/140) than others (58/164), p< 0.001. However, fam-
ily socioeconomic class, ethnicity, and nutritional status (defined
using weight-for-age) were not significantly associated with sero-
protection against tetanus. Age-specific prevalence and risk of
non-protective tetanus immunity by age as detected by ELISA
and TQS were as shown in Table 3. For both ELISA and TQS
test results, a statistically significant trend was demonstrated with
prevalence of non-protection increasing as age increases. Partic-
ipants aged 8 years had the highest prevalence of non-protection
against tetanus.
TQS VALIDATION AGAINST THE ELISA
The ELISA anti-tetanus IgG levels ranged from 0.0064 to
2.4441 IU/ml and the distribution of these levels according to the
initial interpretation of the TQS (positive and negative) is sum-
marized in Figure 2. The box plot (Figure 2) represents the 25th
and 75th percentiles, the line inside the box represents the median
and the lower and upper bars correspond to the 2.5th and 97.5th
percentiles, respectively. The dotted line at 0.1 IU/ml represents
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Table 1 |Tetanus-related vaccination status of study patients.
Vaccination card seen (n=196) Obtained history only (n=108) Total (n=304)
n % of 196 % of 304 n % of 108 % of 304 n %
Completed immunization 28 14.3 9.2 62 57.4 20.4 90 29.6
TETANUS ANTIGEN
DPT-1 164 83.7 53.9 105 97.2 34.5 269 88.5
DPT-2 94 48.0 30.9 99 91.7 32.6 193 63.5
DPT-3 58 29.6 19.1 91 84.3 29.9 149 49.0
Recent TT injection 8 4.1 2.6 17 15.5 5.6 25 8.2
Table 2 |Tetanus-related vaccination status by gender and birth position of study patients.
Tetanus antigen Gender Birth position
Male (170) Female (134) p First born (140) Not first born (164) p
n % n % n % n %
DPT-1 148 87.1 121 90.3 0.189 124 88.6 145 88.4 0.483
DPT-2 110 64.7 83 61.9 0.309 91 65.0 102 62.2 0.306
DPT-3 81 47.6 68 50.7 0.296 69 49.3 80 48.8 0.465
Table 3 | Prevalence and risk of non-protective tetanus immunity by age of study patients.
Age (years) N Non-protection detected byTQS Non-protection detected by ELISA
n (%) OR (95% CI) n (%) OR (95% CI)
1 52 22 (42.3) 1.00 24 (46.2) 1.00
2 60 24 (40.0) 0.91 (0.43, 1.93) 24 (40.0) 0.78 (0.37, 1.65)
3 61 33 (54.1) 1.61 (0.76, 3.39) 35 (57.4) 1.57 (0.75, 3.31)
4 34 26 (76.5) 4.43 (1.69, 11.63) 25 (73.5) 3.24 (1.27, 8.27)
5 34 24 (70.6) 3.27 (1.30, 8.21) 24 (70.6) 2.80 (1.12, 7.01)
6 16 8 (50.0) 1.36 (0.44, 4.20) 8 (50.0) 1.17 (0.38, 3.58)
7 12 6 (50.0) 1.36 (0.39, 4.80) 6 (50.0) 1.17 (0.33, 4.10)
8 18 16 (88.9) 10.91 (2.27, 52.41) 15 (83.3) 5.83 (1.51, 22.60)
9 17 7 (41.2) 0.95 (0.31, 2.90) 7 (41.2) 0.82 (0.27, 2.48)
Total 304 166 (54.6) – 168 (55.3) –
Chi square for trend=6.672; p=0.009 for TQS.
Chi square for trend=4.081; p=0.043 for ELISA.
the cut-off that defines tetanus seroprotection. The median anti-
tetanus IgG level for patients with a positive TQS of 1.5380 IU/ml
(IQR= 1.2677–1.7353) was considerably higher than for those
with a negative TQS of 0.0803 IU/ml (IQR= 0.0464–0.6911).
Table 4 shows the comparison between TQS and the anti-tetanus
IgG concentrations measured by ELISA method using the cut-
off of 0.1 IU/ml. The agreement between the ELISA and the TQS
results was good with a k coefficient of 0.93 (p< 0.001). On the
basis of Table 4, the TQS sensitivity= 97.1% (95% CI= 94.2,
99.9%), specificity= 96.4% (95% CI= 93.6, 99.2%), positive
predictive value (PPV)= 95.7.0% (95% CI= 92.3, 99.1%), and
NPV= 97.6% (95% CI= 95.3, 99.9%).
IDENTIFICATION OF PREDICTIVE FACTORS FOR NON-PROTECTION
AGAINST TETANUS
Out of seven factors investigated in this study, gender, age, posi-
tion of the participants among mother’s children, and history of
recent TT injection were significantly associated with seropro-
tection in bivariate analysis (Table 5). Among the four variables
stated above, only three were identified as independent predictors
of non-protective antibody level (Table 5). Sex had the strongest
influence on level of immunity against tetanus. A male compared
to a female child was 2.37 times more and not being the first
compared to being the first child was 2.10 times more likely to
have non-protective immunity against tetanus. Also, an increase
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FIGURE 2 | Distribution of the anti-tetanus toxoid IgG titers as
determined by ELISA amongTQS positive and negative patients.
Table 4 | Comparison betweenTQS and the anti-tetanus toxoid IgG
concentrations measured by ELISA method (threshold 0.11 IU/ml).
Anti-tetanus toxoid
IgG concentrations
Total
≥0.11 IU/ml <0.11 IU/ml
TQS positive 132 (95.7%) 6 (4.3%) 138 (100.0)
TQS negative 4 (2.4%) 162 (97.6%) 166 (100.0)
Total 136 (44.7%) 168 (55.3%) 304 (100.0)
of 1-year in age has a 15% (95% CI 4–28%) increase in odds of
having non-protective immunity against tetanus.
DISCUSSION
This study has revealed that the prevalence of protection against
tetanus among children hospitalized in a tertiary hospital in Nige-
ria using ELISA and TQS methods was 44.7 and 45.4% respec-
tively; and TQS is good test kit for assessing tetanus immunity.
Also, the data showed that gender, age, and position of the child
(whether first or not) independently predicted non-protective
level of immunity against tetanus. The lack of association between
tetanus-related immunization status and gender nor birth position
suggests that the significantly higher seroprotection in females and
in first born children could not have been because they were more
likely to be vaccinated. The low proportion of children with pro-
tective level of immunity against tetanus in this study underscores
the need to reappraise the current childhood tetanus immuniza-
tion policy in Nigeria. Whilst the DPT-3 coverage rate among
these hospitalized children was 49.0%, we found out that 64.5% of
the children had DPT-3 as evidenced by immunization card. This
immunization rate is considerably less than the recommended
80% required for the entire country (21), but it is higher than full
immunization rate of 23% currently reported for Nigeria (22).
High DPT-1 to DPT-3 vaccine uptake dropout rate found in the
study had also been previously reported (23). Oladokun et al. (23)
reported a dropout rate of 32.1% among children of female traders
in the same city of Ibadan, Nigeria.
That risk of non-protection against tetanus increases with
increasing age was not surprising. Previous reports have shown
that immunity against tetanus wanes with increasing age (5). Many
of the caregivers who participated in the study could not provide
tetanus immunization card, therefore it may be rational to admin-
ister booster dose of TT to children in similar situation, especially if
they are male, not first born of their mothers and history of recent
TT injection is lacking. In addition, children who present with
tetanus-prone wound in the emergency unit would benefit from
anti-tetanus immunoglobulin (5). The strategy of immunizing at
every opportunity is recommended by the Global Advisory Group
of the WHO Expanded Programme on Immunization (EPI) since
1983 (24). However, this is not currently been done for tetanus
vaccination in children in many health facilities. Given the low
level of seroprotection among the study patients, immunizations
need to be offered at every contact point, including preventive and
curative health services. An opportunity for immunization is con-
sidered missed when a person who is eligible for immunization
and who has no contraindication to immunization visits a health
service and does not receive all the needed vaccines. In Niger-
ian settings, eliminating missed opportunities may likely raise the
overall immunization coverage.
There is no universal agreement regarding the absolute sero-
protective level of immunity against tetanus. Protection is only
observed when there are enough antibodies to neutralize the toxin
with regard to the amount of toxin (5). The choice of the cut-
off for protective level of anti-tetanus used in this study was
based on the best compromise between the sensitivity and the
specificity as defined by receiver–operator characteristic curves,
as well as by the work of Simonsen et al. (15). These authors
(15) also demonstrated that the correlation between the ELISA
method and in vivo seroneutralization techniques was poor above
this threshold for individuals with incomplete vaccination. Since
appropriate prophylaxis is the basis of tetanus prevention based
on the characteristics of the wound and on the patient’s immunity
status, it is important to device an objective method of decid-
ing who require tetanus immunoglobulin injection and/or toxoid.
Currently in Nigeria, evaluation of immunity only takes the vacci-
nation history into account. Thus, the TQS test could be helpful in
assessing immunity against tetanus by age in an effort to fine-tune
the optimal timing of booster doses in Nigeria.
This present study shows that TQS could be a good tool in
the evaluation of immunity against tetanus in children. The test
was validated using the ELISA method as the gold standard. The
agreement between the two tests was high, given the k concordance
coefficient of 0.93. This value is higher than 0.71 (14), and 0.77
(16) found in a similar evaluations. The sensitivity (95.7%) was
higher than that found in other studies (12–14). The NPVs 96.0%
and a negative TQS test would be false negative in only 2.4% of
cases with the practical consequence of giving an unnecessary anti-
tetanus prophylaxis. However, an over-protected child is evidently
more tolerable than a patient wrongly considered to be protected.
Moreover, a specificity of 97.6% and a PPV of 98.0% implying
that a positive test is thus a true positive in 95.7% of cases in the
observed seroprevalence, when a threshold of 0.1 IU/ml is chosen.
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Table 5 | Potential risk factors for non-protective tetanus immunity among study patients.
Factors N Not protected UOR AOR
n % OR 95% CI OR 95% CI
GENDER
Male 170 108 63.5 2.15 1.35, 3.41 2.37 1.45, 3.87
Femalea 134 60 44.8 1 – 1 –
Age (years)b 304 168 55.3 1.11 1.01, 1.22 1.15 1.04, 1.28
POSITIONc
First borna 140 62 44.3 1 – 1 –
Not first 164 106 64.6 2.29 1.45, 3.65 2.10 1.26, 3.51
HISTORY RECENTTT
Yesa 25 8 32.0 1 1 –
No 279 160 57.3 2.86 1.19, 6.84 0.38 0.15, 1.00
Ethnicity
Yoruba 244 138 56.6 1.30 0.74, 2.29
Non-Yorubaa 60 30 50.0 1 –
PARENTS’ SOCIAL CLASS
Higha 24 12 50.0 1 –
Middle 98 55 56.1 1.28 0.53, 3.13
Low 182 101 55.5 1.25 0.53, 2.92
NUTRITIONAL STATUS
WAZ<2.0 75 46 61.3 1.39 0.82, 2.37
WAZ≥2.0a 229 122 53.3 1 –
aReference category
bContinuous variable
cPosition among mother’s children.
UOR, unadjusted odds ratio; AOR, adjusted odds ratio;WAZ, weight-for-age z-score.
These values are comparable to reported values in other studies
using the same threshold (12–14). The implications of these per-
formance results are: a patient with a positive test had a 98.0%
probability of having an antitoxin level higher than 0.1 IU/ml
while a negative test indicated a 96.0% probability of having an
anti-tetanus level less than 0.1 IU/ml. TQS thus provides an objec-
tive evidence for assessment of tetanus immunity. In situations of
incorrect or doubtful history from caregivers, its use could improve
the administration of anti-tetanus prophylaxis.
The high performance of the TQS test by the bedside obtained
in this study confirms the importance and benefit of this test over
the usual clinical history taking. However, its use in children emer-
gency units should not be considered without a quality assurance
process and corroboration of both laboratory and clinical judg-
ments. There is the need to conduct a cost-effectiveness study to
compare the different strategies for tetanus prophylaxis treatment
for wounds; test all, or treat those who are suspected to be unpro-
tected. Compared to ELISA technique, used to measure the level of
antibody against tetanus, TQS offers some advantages: the result is
quick, relatively painless, and does not require venous blood sam-
pling. The sampling of a drop of capillary blood at the fingertip
is a relatively less invasive procedure and may be more acceptable
to children than venepuncture. The TQS test is practicable at the
bedside by any healthcare provider in an emergency unit. Never-
theless, it will cost about eight US Dollars (approximately 1,500
Naira) but this is not in any way comparable to high cost of treat-
ing tetanus and high mortality rate. Another challenge with TQS
is that interpretation of the test is not always easy. Equivocal TQS
results are not infrequent (13, 14). Indeed, six tests were inter-
preted as equivocal (2%) by the research assistant in this study.
In our experience, a discontinuous or whitish strip which is diffi-
cult to visualize occurred occasionally with intermediate/declining
protection. In such cases, it is safer to consider TQS as negative and
boost the child’s immunity, especially in wounds that are difficult
to clean. With good training, TQS is reproducible by all healthcare
professionals (25).
One factor that could limit the interpretation and generaliza-
tion of data presented in this study is that 33 (10.9%) of eligible
children did not participate. Though age and sex distributions
of these children were similar to participants’, it was impossible
to assess their level immunity against tetanus. It therefore remains
unknown from the data whether their inclusion in the study might
have altered the results, especially the prevalence estimates. There
is the need for further study to estimate the number of cases in
which the TQS result would have modified the decision to give
prophylaxis on the basis of the history in patients and cost-benefit
analysis. Another factor that needs to be considered in the interpre-
tation of data on seroprotection in this study is the predominance
of children 5 years and below in the study population. However,
the pattern of age distribution observed in this study is similar to
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what has been previous reported in the same emergency unit for
many other disease conditions (26, 27).
In conclusion, lack of protective immunity against tetanus is
frequent among hospitalized children in Nigeria. Age, gender, and
position among mother’s children were identified as indepen-
dent predictive factors for non-protective level of immunity. In
this study, because the WHO schedule for infant DTP doses rec-
ommends an accelerated schedule with doses given prior to full
immune system maturity (4), there are good grounds to be con-
cerned that immunity wanes relatively early in childhood. The
TQS proved to be a reliable tool for the evaluation of immunity to
tetanus. The use of TQS, in combination with the vaccination his-
tory has the potential to improve evaluation of tetanus immunity,
which is essential to optimize prophylaxis policy in Nigerian chil-
dren. However, bearing in mind the possibility of false positive
results with TQS, we suggest anti-tetanus immunoglobulin or tox-
oid be given to children who cannot afford the cost of testing
for immunity level and has any of the identified risk factors for
non-protection.
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